Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perinatal/Neonatal Casebook
  • Published:

Perinatal/Neonatal Case Book

Treatment of Severe Pulmonary Hemorrhage With Activated Recombinant Factor VII (rFVIIa) in Very Low Birth Weight Infants

Journal of Perinatology volume 22, pages 672–674 (2002)Cite this article

Abstract

Clinically apparent pulmonary hemorrhage (PH) occurs in 5% to 7% of very low birth weight (VLBW) infants with respiratory distress syndrome (RDS). It is associated with a mortality rate as high as 50% and significant pulmonary and central nervous system morbidities. There is no consensus on treatment modality. We present two VLBW infants with severe PH that did not respond to conventional treatment but were successfully treated with activated recombinant factor VII (rFVIIa). No untoward side effects were noted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Pandit PB, O'Brien K, Asztalos E, Colucci E, Dunn MS . Outcome following pulmonary hemorrhage in very low birthweight neonates treated with surfactant Arch Dis Child Fetal Neonatal Ed 1999 81: F40–4

    Article  CAS  Google Scholar 

  2. Tomaszewska M, Stork E, Minich NM, Friedman H, Berlin S, Hack M . Pulmonary hemorrhage: clinical course and outcomes among very low-birth-weight infants Arch Pediatr Adolesc Med 1999 153: 715–21

    Article  CAS  Google Scholar 

  3. Raju TN, Langenberg P . Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis J Pediatr 1993 123: 603–10

    Article  CAS  Google Scholar 

  4. Lusher JM, Roberts HR, Davignon G et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group Haemophilia 1998 4: 790–8

    Article  CAS  Google Scholar 

  5. Hedner U . Recombinant activated factor VII as a universal haemostatic agent Blood Coagul Fibrinolysis 1998 9: Suppl 1 147–52

    Google Scholar 

  6. Berger TM, Allred EN, Van Marter LJ . Antecedents of clinically significant pulmonary hemorrhage among newborn infants J Perinatol 2000 20: 295–300

    Article  CAS  Google Scholar 

  7. Garland J, Buck R, Weinberg M . Pulmonary hemorrhage risk in infants with a clinically diagnosed patent ductus arteriosus: a retrospective cohort study Pediatrics 1994 94: 719–23

    CAS  PubMed  Google Scholar 

  8. Thibeault DW, Hall FK, Sheehan MB, Hall RT . Postasphyxial lung disease in newborn infants with severe perinatal acidosis Am J Obstet Gynecol 1984 150: 393–9

    Article  CAS  Google Scholar 

  9. Trompeter R, Yu VY, Aynsley-Green A, Roberton NR . Massive pulmonary hemorrhage in the newborn infant Arch Dis Child 1975 50: 123–7

    Article  CAS  Google Scholar 

  10. Kluckow M, Evans N . Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage J Pediatr 2000 137: 68–72

    Article  CAS  Google Scholar 

  11. Hedner U . NovoSeven as a universal haemostatic agent Blood Coagul Fibrinolysis 2000 11: Suppl 1 S107–11

    Article  CAS  Google Scholar 

  12. Monroe DM, Hoffman M, Oliver JA, Roberts HR . A possible mechanism of action of activated factor VII independent of tissue factor Blood Coagul Fibrinolysis 1998 9: Suppl 1 S15–20

    CAS  PubMed  Google Scholar 

  13. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U . High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system Br J Haematol 2001 114: 114–20

    Article  CAS  Google Scholar 

  14. Arkin S, Cooper HA, Hutter JJ et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program Haemostasis 1998 28: 93–8

    CAS  PubMed  Google Scholar 

  15. Chuansumrit A, Chantarojanasiri T, Isarangkura P, Teeraratkul S, Hongeng S, Hathirat P . Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation Blood Coagul Fibrinolysis 2000 11: Suppl 1 S101–5

    Article  CAS  Google Scholar 

  16. Kristensen J, Killander A, Hippe E et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia Haemostasis 1996 26: Suppl 1 159–64

    CAS  PubMed  Google Scholar 

  17. Friederich PW, Wever PC, Briet E, Doorenbos CJ, Levi M . Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease Am J Hematol 2001 66: 292–4

    Article  CAS  Google Scholar 

  18. Wong WY, Huang WC, Miller R, McGinty K, Whisnant JK . Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency Haemophilia 2000 6: 50–4

    Article  CAS  Google Scholar 

  19. Duncan A, Benson L, Critz A, Abshire T . Neonatal coagulopathy treatment with rFVIIa Pediatr Res 2001 49: 290A

    Google Scholar 

  20. Shapiro A . Inhibitor treatment: state of the art Semin Hematol 2001 38: 26–34

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics and Human Development, Division of Neonatology, Michigan State University, East Lansing, MI, USA

    Nicholas Olomu MD

  2. Department of Pediatrics and Human Development, Division of Hematology-Oncology, Michigan State University, East Lansing, MI, USA

    Roshni Kulkarni MD

  3. Mountain States Regional Hemophilia and Thrombosis Center, University of Colorado Health Sciences Center, Aurora, CO, USA

    Marilyn Manco-Johnson MD

Authors
  1. Nicholas Olomu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roshni Kulkarni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marilyn Manco-Johnson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olomu, N., Kulkarni, R. & Manco-Johnson, M. Treatment of Severe Pulmonary Hemorrhage With Activated Recombinant Factor VII (rFVIIa) in Very Low Birth Weight Infants. J Perinatol 22, 672–674 (2002). https://doi.org/10.1038/sj.jp.7210787

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7210787

This article is cited by

Search

Advanced search

Quick links